{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:56:10Z","timestamp":1777312570073,"version":"3.51.4"},"reference-count":120,"publisher":"Hamad bin Khalifa University Press (HBKU Press)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the only zoonotic-origin CoV to reach the pandemic stage, to which neither an effective vaccine nor a specific therapy is available. The spike glycoprotein harbors the receptor-binding domain (RBD) that mediates the virus's entry to host cells. This study aimed to identify novel inhibitors that target the spike protein's RBD domain through computational screening of chemical and natural compounds.\n                    <jats:bold>Method:<\/jats:bold>\n                    The spike protein was modeled from the recently reported electron microscopy protein structure (PDB ID: 6VSB) and the previously described SARS-CoV protein structure (PDB ID: 6ACD and 6ACJ). Virtual lab bench CLC Drug Discovery was used to computationally screen for potential inhibitory effects of currently prescribed drugs (n\u00a0=\u00a022), natural antiviral drugs (n\u00a0=\u00a0100), and natural compounds (n\u00a0=\u00a035032). Quantitative Structure-Activity Relationship (QSAR) studies were also performed to determine the leading binders known for their antiviral activity.\n                    <jats:bold>Results:<\/jats:bold>\n                    Among the drugs currently used to treat SARS-CoV2, hydroxychloroquine and favipiravir were identified as the best binders with an average of four H-bonds, with a binding affinity of \u2212\u00a036.66 kcal\/mol and a minimum interaction energy of \u2212\u00a06.63 kcal\/mol. In an evaluation of antiviral compounds, fosamprenavir and abacavir showed effective binding of five H-bonds, with an average binding affinity of \u2212\u00a018.75 kcal.mol\n                    <jats:sup>\u2212\u00a01<\/jats:sup>\n                    and minimum interaction energy of \u2212\u00a03.57 kcal\/mol. Furthermore, screening of 100 natural antiviral compounds predicted potential binding modes of glycyrrhizin, nepritin, punicalagin, epigallocatechin gallate, and theaflavin (average binding affinity of \u2212\u00a049.88 kcal\/mol and minimum interaction energy of \u2212\u00a04.35 kcal\/mol). Additionally, the study reports a list of 25 natural compounds that showed effective binding with an improved average binding affinity of \u2212\u00a051.46 kcal\/mol.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Using computational screening, we identified potential SARS-CoV-2 S glycoprotein inhibitors that bind to the RBD region. Using structure-based design and combination-based drug therapy, the identified molecules could be used to generate anti-SARS-CoV-2 drug candidates.\n                  <\/jats:p>","DOI":"10.5339\/qmj.2021.12","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T05:30:49Z","timestamp":1615786249000},"source":"Crossref","is-referenced-by-count":13,"title":["Identification of potential natural inhibitors of the receptor-binding domain of the SARS-CoV-2 spike protein using a computational docking approach"],"prefix":"10.5339","volume":"2021","author":[{"given":"Shilu Mathew","family":"Mathew","sequence":"first","affiliation":[{"name":"Biomedical Research Center, Qatar University, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatiha","family":"Benslimane","sequence":"additional","affiliation":[{"name":"Biomedical Research Center, Qatar University, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asmaa A.","family":"Althani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi M.","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3277","reference":[{"issue":"(8)","key":"CIT0001","series-title":"N Engl J Med","first-page":"727\u201333","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu\n \nN\n,","year":"2020"},{"key":"CIT0002","series-title":"Eur Radiol","article-title":"The role of imaging in 2019 novel coronavirus pneumonia (COVID-19)","author":"Yang\n \nW\n,","year":"2020"},{"issue":"(4)","key":"CIT0003","series-title":"J Med Virol","first-page":"418\u201323","article-title":"Emerging coronaviruses: Genome structure, replication, and pathogenesis","volume":"92","author":"Chen\n \nY\n,","year":"2020"},{"issue":"(4)","key":"CIT0004","series-title":"J Infect Public Health","first-page":"644\u20136","article-title":"The outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global health threat","volume":"13","author":"Arshad Ali\n \nS\n,","year":"2020"},{"key":"CIT0005","article-title":"Naming the coronavirus disease (COVID-19) and the virus that causes it","year":"2020"},{"issue":"(10)","key":"CIT0006","series-title":"Int J Biol Sci","first-page":"1678\u201385","article-title":"SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat","volume":"16","author":"Zheng\n \nJ","year":"2020"},{"issue":"(6)","key":"CIT0007","series-title":"Clin Microbiol Infect","first-page":"729\u201334","article-title":"COVID-19, SARS and MERS: are they closely related?","volume":"26","author":"Petrosillo\n \nN\n,","year":"2020"},{"issue":"(1)","key":"CIT0008","series-title":"Acta bio-medica: Atenei Parmensis","first-page":"157\u201360","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta\n \nD\n,","year":"2020"},{"issue":"9","key":"CIT0009","series-title":"Drugs Context","article-title":"Pharmacological treatment of COVID-19: lights and shadows","author":"Menzella\n \nF\n,","year":"2020"},{"issue":"(4)","key":"CIT0010","series-title":"Immunity","first-page":"583\u20139","article-title":"SARS-CoV-2 Vaccines: Status Report","volume":"52","author":"Amanat\n \nF\n,","year":"2020"},{"issue":"(3)","key":"CIT0011","series-title":"J Microbiol Biotechnol","first-page":"313\u201324","article-title":"Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)","volume":"30","author":"Ahn\n \nDG\n,","year":"2020"},{"key":"CIT0012","series-title":"Curr Trop Med Rep","first-page":"1\u20134","article-title":"The SARS-CoV-2 Vaccine Pipeline: an Overview","author":"Chen\n \nWH\n,","year":"2020"},{"issue":"(5)","key":"CIT0013","series-title":"Nat Rev Drug Discov","first-page":"327\u201347","article-title":"Coronaviruses - drug discovery and therapeutic options","volume":"15","author":"Zumla\n \nA\n,","year":"2016"},{"issue":"(6)","key":"CIT0014","series-title":"Cell Mol Immunol","first-page":"613\u201320","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai\n \nW\n,","year":"2020"},{"issue":"(7807)","key":"CIT0015","series-title":"Nature","first-page":"221\u20134","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang\n \nJ\n,","year":"2020"},{"issue":"(8)","key":"CIT0016","series-title":"PLoS Pathog","first-page":"e1007236\u2013e","article-title":"Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2","volume":"14","author":"Song\n \nW\n,","year":"2018"},{"issue":"(6483)","key":"CIT0017","series-title":"Science (New York, NY)","first-page":"1260\u20133","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp\n \nD\n,","year":"2020"},{"issue":"(10)","key":"CIT0018","series-title":"Biophys J","first-page":"2525\u201334","article-title":"Improving the physical realism and structural accuracy of protein models by a two-step atomic-level energy minimization","volume":"101","author":"Xu\n \nD\n,","year":"2011"},{"issue":"(2)","key":"CIT0019","series-title":"J Appl Crystallogr","first-page":"283\u201391","article-title":"PROCHECK: a program to check the stereochemical quality of protein structures","volume":"26","author":"Laskowski\n \nRA\n,","year":"1993"},{"issue":"(suppl_2):","key":"CIT0020","series-title":"Nucleic Acids Res","first-page":"W590\u2013W4","article-title":"SuperPose: a simple server for sophisticated structural superposition","volume":"32","author":"Maiti\n \nR\n,","year":"2004"},{"issue":"(3)","key":"CIT0021","series-title":"Proteins","first-page":"195\u2013202","article-title":"Automated docking of substrates to proteins by simulated annealing","volume":"8","author":"Goodsell\n \nDS\n,","year":"1990"},{"issue":"(3)","key":"CIT0022","series-title":"Infect Chemother","first-page":"212\u201322","article-title":"Antiviral Treatment Guidelines for Middle East Respiratory Syndrome","volume":"47","author":"Chong\n \nYP\n,","year":"2015"},{"key":"CIT0023","article-title":"ACD\/ChemSketch Toronto, ON, Canada,: Advanced Chemistry Development, Inc.;","year":"2019"},{"issue":"(D1):","key":"CIT0024","series-title":"Nucleic Acids Res","first-page":"D1217\u2013d22","article-title":"NPASS: natural product activity and species source database for natural product research, discovery and tool development","volume":"46","author":"Zeng\n \nX\n,","year":"2018"},{"key":"CIT0025","series-title":"Nat Biotechnol","first-page":"71","article-title":"Structure-based maximal affinity model predicts small-molecule druggability","volume":"25","author":"Cheng\n \nAC\n,","year":"2007"},{"key":"CIT0026","series-title":"Denmark: QIAGEN Aarhus","article-title":"CLC Drug Discovery Workbench 3.0.2 Manual. In: Aarhus Q, editor","year":"2017"},{"issue":"(3)","key":"CIT0027","series-title":"Nat Rev Drug Discov","first-page":"192\u2013204","article-title":"ADMET in silico modelling: towards prediction paradise?","volume":"2","author":"van de Waterbeemd\n \nH\n,","year":"2003"},{"key":"CIT0028","article-title":"Istituto di Ricerche Farmacologiche Mario Negri Milano VEGA (based on CAESAR project). version 1.0.8"},{"issue":"(1)","key":"CIT0029","series-title":"Virol J","first-page":"73","article-title":"The SARS Coronavirus S Glycoprotein Receptor Binding Domain: Fine Mapping and Functional Characterization","volume":"2","author":"Chakraborti\n \nS\n,","year":"2005"},{"issue":"(5\u20136)","key":"CIT0030","series-title":"J Comput Chem","first-page":"553\u201386","article-title":"Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94","volume":"17","author":"Halgren\n\nTA","year":"1998"},{"issue":"(6)","key":"CIT0031","series-title":"J Comput Aided Mol Des","first-page":"775\u201386","article-title":"Variability in docking success rates due to dataset preparation","volume":"26","author":"Corbeil\n \nCR\n,","year":"2012"},{"issue":"(10\u201311)","key":"CIT0032","series-title":"J Comput Aided Mol Des","first-page":"647\u201371","article-title":"PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results","volume":"20","author":"Dixon\n \nSL\n,","year":"2006"},{"issue":"(5\u20136)","key":"CIT0033","series-title":"J Comput Aided Mol Des","first-page":"553\u201386","article-title":"Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94","volume":"17","author":"Halgren\n \nTA","year":"1996"},{"key":"CIT0034","series-title":"Cell Mol Immunol","article-title":"Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV","author":"Zheng\n \nM\n,","year":"2020"},{"key":"CIT0035","series-title":"J Biomol Struct Dyn","first-page":"1\u201311","article-title":"Docking study of Chloroquine and Hydroxychloroquine interaction with SARS-CoV-2 spike glycoprotein-An in silico insight into the comparative efficacy of repurposing antiviral drugs","volume":"2020:","author":"Amin\n \nM\n,"},{"key":"CIT0036","series-title":"J Biomol Struct Dyn","first-page":"1\u201311","article-title":"In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel","author":"Gupta\n \nMK\n,","year":"2020"},{"issue":"(6)","key":"CIT0037","series-title":"Ophthalmology","first-page":"1386\u201394","article-title":"Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)","volume":"123","author":"Marmor\n \nMF\n,","year":"2016"},{"issue":"(1)","key":"CIT0038","series-title":"Cell Discov","first-page":"1\u20134","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu\n \nJ\n,","year":"2020"},{"key":"CIT0039","series-title":"Clinical Infect Dis","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao\n \nX\n,","year":"2020"},{"issue":"(5)","key":"CIT0040","series-title":"Acta Pharm Sin B","first-page":"766\u201388","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu\n \nC\n,","year":"2020"},{"issue":"(2)","key":"CIT0041","series-title":"Adv J Chem B","first-page":"55\u201360","article-title":"Favipiravir: Structural Analysis and Activity against COVID-19","volume":"2","author":"Harismah\n \nK\n,","year":"2020"},{"issue":"(3)","key":"CIT0042","series-title":"Curr Pharmacol Rep","first-page":"56\u201370","article-title":"An Update on Current Therapeutic Drugs Treating COVID-19","volume":"6","author":"Wu\n \nR\n,","year":"2020"},{"key":"CIT0043","series-title":"Eurasian J Med Oncol","first-page":"185\u2013195","article-title":"The molecular docking study of potential drug candidates showing anti-COVID-19 activity by exploring of therapeutic targets of SARS-CoV-2","volume":"4","author":"Narkhede\n \nRR\n,"},{"issue":"(5)","key":"CIT0044","series-title":"Biointerface Research in Applied Chemistry","first-page":"6444\u201359","article-title":"Molecular Docking Studies of some Antiviral and Antimalarial Drugs Via Bindings to 3CL-Protease and Polymerase Enzymes of the Novel Coronavirus (SARS-CoV-2)","volume":"10","author":"Al-Masoudi\n \nNAE\n,","year":"2020"},{"issue":"(7)","key":"CIT0045","series-title":"Proc Jpn Acad Ser B","first-page":"449\u201363","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta\n \nY\n,","year":"2017"},{"issue":"(71)","key":"CIT0046","series-title":"Acta Pharmaceutica Sinica B","first-page":"163\u201374","article-title":"Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies","volume":"1","author":"Daoud S\n \nAS\n,","year":"2021"},{"key":"CIT0047","series-title":"AIDS","first-page":"268\u20139","article-title":"Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir\/ritonavir regimen","volume":"21:","author":"Pavel S \n \nBC\n,","year":"2007"},{"issue":"(2\u20133):","key":"CIT0048","series-title":"Antiviral Res","first-page":"171\u20137","article-title":"Therapeutic basis of glycyrrhizin on chronic hepatitis B","volume":"30","author":"Sato\n \nH\n,","year":"1996"},{"issue":"(4)","key":"CIT0049","series-title":"J Med Chem","first-page":"1256\u20139","article-title":"Antiviral Activity of Glycyrrhizic Acid Derivatives against SARS\u00a0\u2212\u00a0Coronavirus","volume":"48","author":"Hoever\n \nG\n,","year":"2005"},{"issue":"(9374)","key":"CIT0050","series-title":"Lancet","first-page":"2045\u20136","article-title":"Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus","volume":"361","author":"Cinatl\n \nJ\n,","year":"2003"},{"key":"CIT0051","series-title":"Pharmacol Ther","first-page":"107618\u2013","article-title":"Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?","volume":"214:","author":"Bailly\n \nC\n,","year":"2020"},{"issue":"(3)","key":"CIT0052","series-title":"Agents and Actions","first-page":"298\u2013302","article-title":"The anti-inflammatory action of nepitrin, a flavonoid","volume":"12","author":"Agarwal\n \nOP","year":"1982"},{"key":"CIT0053","series-title":"Mol Cell Biochem","article-title":"Computational study of pomegranate peel extract polyphenols as potential inhibitors of SARS-CoV-2 virus internalization","author":"Suruc\u02c7ic\u2032\n \nR\n,","year":"2020"},{"issue":"(1)","key":"CIT0054","series-title":"BMC Complement Alternative Med","first-page":"47","article-title":"Anti-inflammatory potential of ellagic acid, gallic acid and punicalagin A&B isolated from Punica granatum","volume":"17","author":"BenSaad\n \nLA\n,","year":"2017"},{"key":"CIT0055","series-title":"Bioinform Biol Insights","first-page":"14:1177932220965505","article-title":"Targeting the GRP78-Dependant SARS-CoV-2 Cell Entry by Peptides and Small Molecules","author":"Allam\n \nL\n,","year":"2020"},{"key":"CIT0056","series-title":"Drug Dev Res","first-page":":10.1002\/ddr.21730","article-title":"Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study","author":"Maiti\n \nS\n,","year":"2020"},{"issue":"(1)","key":"CIT0057","series-title":"Scientific Reports","first-page":"13093","article-title":"In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication","volume":"10","author":"Touret\n \nF\n,","year":"2020"},{"issue":"(10)","key":"CIT0058","series-title":"NatRevi Microbiol","first-page":"593\u2013606","article-title":"Therapeutic strategies to target the Ebola virus life cycle","volume":"17","author":"Hoenen\n \nT\n,","year":"2019"},{"key":"CIT0059","series-title":"Antiviral Res","first-page":"165\u201372","article-title":"Synergistic drug combination effectively blocks Ebola virus infection","volume":"137:","author":"Sun\n \nW\n,","year":"2017"},{"issue":"(2)","key":"CIT0060","series-title":"Br J Pharmacol","first-page":"181\u201391","article-title":"Drug repurposing screens and synergistic drug-combinations for infectious diseases","volume":"175","author":"Zheng\n \nW\n,","year":"2018"},{"issue":"(8)","key":"CIT0001","series-title":"N Engl J Med","first-page":"727\u201333","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu\n \nN\n,","year":"2020"},{"key":"CIT0002","series-title":"Eur Radiol","article-title":"The role of imaging in 2019 novel coronavirus pneumonia (COVID-19)","author":"Yang\n \nW\n,","year":"2020"},{"issue":"(4)","key":"CIT0003","series-title":"J Med Virol","first-page":"418\u201323","article-title":"Emerging coronaviruses: Genome structure, replication, and pathogenesis","volume":"92","author":"Chen\n \nY\n,","year":"2020"},{"issue":"(4)","key":"CIT0004","series-title":"J Infect Public Health","first-page":"644\u20136","article-title":"The outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global health threat","volume":"13","author":"Arshad Ali\n \nS\n,","year":"2020"},{"key":"CIT0005","article-title":"Naming the coronavirus disease (COVID-19) and the virus that causes it","year":"2020"},{"issue":"(10)","key":"CIT0006","series-title":"Int J Biol Sci","first-page":"1678\u201385","article-title":"SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat","volume":"16","author":"Zheng\n \nJ","year":"2020"},{"issue":"(6)","key":"CIT0007","series-title":"Clin Microbiol Infect","first-page":"729\u201334","article-title":"COVID-19, SARS and MERS: are they closely related?","volume":"26","author":"Petrosillo\n \nN\n,","year":"2020"},{"issue":"(1)","key":"CIT0008","series-title":"Acta bio-medica: Atenei Parmensis","first-page":"157\u201360","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta\n \nD\n,","year":"2020"},{"issue":"9","key":"CIT0009","series-title":"Drugs Context","article-title":"Pharmacological treatment of COVID-19: lights and shadows","author":"Menzella\n \nF\n,","year":"2020"},{"issue":"(4)","key":"CIT0010","series-title":"Immunity","first-page":"583\u20139","article-title":"SARS-CoV-2 Vaccines: Status Report","volume":"52","author":"Amanat\n \nF\n,","year":"2020"},{"issue":"(3)","key":"CIT0011","series-title":"J Microbiol Biotechnol","first-page":"313\u201324","article-title":"Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)","volume":"30","author":"Ahn\n \nDG\n,","year":"2020"},{"key":"CIT0012","series-title":"Curr Trop Med Rep","first-page":"1\u20134","article-title":"The SARS-CoV-2 Vaccine Pipeline: an Overview","author":"Chen\n \nWH\n,","year":"2020"},{"issue":"(5)","key":"CIT0013","series-title":"Nat Rev Drug Discov","first-page":"327\u201347","article-title":"Coronaviruses - drug discovery and therapeutic options","volume":"15","author":"Zumla\n \nA\n,","year":"2016"},{"issue":"(6)","key":"CIT0014","series-title":"Cell Mol Immunol","first-page":"613\u201320","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai\n \nW\n,","year":"2020"},{"issue":"(7807)","key":"CIT0015","series-title":"Nature","first-page":"221\u20134","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang\n \nJ\n,","year":"2020"},{"issue":"(8)","key":"CIT0016","series-title":"PLoS Pathog","first-page":"e1007236\u2013e","article-title":"Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2","volume":"14","author":"Song\n \nW\n,","year":"2018"},{"issue":"(6483)","key":"CIT0017","series-title":"Science (New York, NY)","first-page":"1260\u20133","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp\n \nD\n,","year":"2020"},{"issue":"(10)","key":"CIT0018","series-title":"Biophys J","first-page":"2525\u201334","article-title":"Improving the physical realism and structural accuracy of protein models by a two-step atomic-level energy minimization","volume":"101","author":"Xu\n \nD\n,","year":"2011"},{"issue":"(2)","key":"CIT0019","series-title":"J Appl Crystallogr","first-page":"283\u201391","article-title":"PROCHECK: a program to check the stereochemical quality of protein structures","volume":"26","author":"Laskowski\n \nRA\n,","year":"1993"},{"issue":"(suppl_2):","key":"CIT0020","series-title":"Nucleic Acids Res","first-page":"W590\u2013W4","article-title":"SuperPose: a simple server for sophisticated structural superposition","volume":"32","author":"Maiti\n \nR\n,","year":"2004"},{"issue":"(3)","key":"CIT0021","series-title":"Proteins","first-page":"195\u2013202","article-title":"Automated docking of substrates to proteins by simulated annealing","volume":"8","author":"Goodsell\n \nDS\n,","year":"1990"},{"issue":"(3)","key":"CIT0022","series-title":"Infect Chemother","first-page":"212\u201322","article-title":"Antiviral Treatment Guidelines for Middle East Respiratory Syndrome","volume":"47","author":"Chong\n \nYP\n,","year":"2015"},{"key":"CIT0023","article-title":"ACD\/ChemSketch Toronto, ON, Canada,: Advanced Chemistry Development, Inc.;","year":"2019"},{"issue":"(D1):","key":"CIT0024","series-title":"Nucleic Acids Res","first-page":"D1217\u2013d22","article-title":"NPASS: natural product activity and species source database for natural product research, discovery and tool development","volume":"46","author":"Zeng\n \nX\n,","year":"2018"},{"key":"CIT0025","series-title":"Nat Biotechnol","first-page":"71","article-title":"Structure-based maximal affinity model predicts small-molecule druggability","volume":"25","author":"Cheng\n \nAC\n,","year":"2007"},{"key":"CIT0026","series-title":"Denmark: QIAGEN Aarhus","article-title":"CLC Drug Discovery Workbench 3.0.2 Manual. In: Aarhus Q, editor","year":"2017"},{"issue":"(3)","key":"CIT0027","series-title":"Nat Rev Drug Discov","first-page":"192\u2013204","article-title":"ADMET in silico modelling: towards prediction paradise?","volume":"2","author":"van de Waterbeemd\n \nH\n,","year":"2003"},{"key":"CIT0028","article-title":"Istituto di Ricerche Farmacologiche Mario Negri Milano VEGA (based on CAESAR project). version 1.0.8"},{"issue":"(1)","key":"CIT0029","series-title":"Virol J","first-page":"73","article-title":"The SARS Coronavirus S Glycoprotein Receptor Binding Domain: Fine Mapping and Functional Characterization","volume":"2","author":"Chakraborti\n \nS\n,","year":"2005"},{"issue":"(5\u20136)","key":"CIT0030","series-title":"J Comput Chem","first-page":"553\u201386","article-title":"Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94","volume":"17","author":"Halgren\n\nTA","year":"1998"},{"issue":"(6)","key":"CIT0031","series-title":"J Comput Aided Mol Des","first-page":"775\u201386","article-title":"Variability in docking success rates due to dataset preparation","volume":"26","author":"Corbeil\n \nCR\n,","year":"2012"},{"issue":"(10\u201311)","key":"CIT0032","series-title":"J Comput Aided Mol Des","first-page":"647\u201371","article-title":"PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results","volume":"20","author":"Dixon\n \nSL\n,","year":"2006"},{"issue":"(5\u20136)","key":"CIT0033","series-title":"J Comput Aided Mol Des","first-page":"553\u201386","article-title":"Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94","volume":"17","author":"Halgren\n \nTA","year":"1996"},{"key":"CIT0034","series-title":"Cell Mol Immunol","article-title":"Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV","author":"Zheng\n \nM\n,","year":"2020"},{"key":"CIT0035","series-title":"J Biomol Struct Dyn","first-page":"1\u201311","article-title":"Docking study of Chloroquine and Hydroxychloroquine interaction with SARS-CoV-2 spike glycoprotein-An in silico insight into the comparative efficacy of repurposing antiviral drugs","volume":"2020:","author":"Amin\n \nM\n,"},{"key":"CIT0036","series-title":"J Biomol Struct Dyn","first-page":"1\u201311","article-title":"In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel","author":"Gupta\n \nMK\n,","year":"2020"},{"issue":"(6)","key":"CIT0037","series-title":"Ophthalmology","first-page":"1386\u201394","article-title":"Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)","volume":"123","author":"Marmor\n \nMF\n,","year":"2016"},{"issue":"(1)","key":"CIT0038","series-title":"Cell Discov","first-page":"1\u20134","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu\n \nJ\n,","year":"2020"},{"key":"CIT0039","series-title":"Clinical Infect Dis","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao\n \nX\n,","year":"2020"},{"issue":"(5)","key":"CIT0040","series-title":"Acta Pharm Sin B","first-page":"766\u201388","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu\n \nC\n,","year":"2020"},{"issue":"(2)","key":"CIT0041","series-title":"Adv J Chem B","first-page":"55\u201360","article-title":"Favipiravir: Structural Analysis and Activity against COVID-19","volume":"2","author":"Harismah\n \nK\n,","year":"2020"},{"issue":"(3)","key":"CIT0042","series-title":"Curr Pharmacol Rep","first-page":"56\u201370","article-title":"An Update on Current Therapeutic Drugs Treating COVID-19","volume":"6","author":"Wu\n \nR\n,","year":"2020"},{"key":"CIT0043","series-title":"Eurasian J Med Oncol","first-page":"185\u2013195","article-title":"The molecular docking study of potential drug candidates showing anti-COVID-19 activity by exploring of therapeutic targets of SARS-CoV-2","volume":"4","author":"Narkhede\n \nRR\n,"},{"issue":"(5)","key":"CIT0044","series-title":"Biointerface Research in Applied Chemistry","first-page":"6444\u201359","article-title":"Molecular Docking Studies of some Antiviral and Antimalarial Drugs Via Bindings to 3CL-Protease and Polymerase Enzymes of the Novel Coronavirus (SARS-CoV-2)","volume":"10","author":"Al-Masoudi\n \nNAE\n,","year":"2020"},{"issue":"(7)","key":"CIT0045","series-title":"Proc Jpn Acad Ser B","first-page":"449\u201363","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta\n \nY\n,","year":"2017"},{"issue":"(71)","key":"CIT0046","series-title":"Acta Pharmaceutica Sinica B","first-page":"163\u201374","article-title":"Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies","volume":"1","author":"Daoud S\n \nAS\n,","year":"2021"},{"key":"CIT0047","series-title":"AIDS","first-page":"268\u20139","article-title":"Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir\/ritonavir regimen","volume":"21:","author":"Pavel S \n \nBC\n,","year":"2007"},{"issue":"(2\u20133):","key":"CIT0048","series-title":"Antiviral Res","first-page":"171\u20137","article-title":"Therapeutic basis of glycyrrhizin on chronic hepatitis B","volume":"30","author":"Sato\n \nH\n,","year":"1996"},{"issue":"(4)","key":"CIT0049","series-title":"J Med Chem","first-page":"1256\u20139","article-title":"Antiviral Activity of Glycyrrhizic Acid Derivatives against SARS\u00a0\u2212\u00a0Coronavirus","volume":"48","author":"Hoever\n \nG\n,","year":"2005"},{"issue":"(9374)","key":"CIT0050","series-title":"Lancet","first-page":"2045\u20136","article-title":"Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus","volume":"361","author":"Cinatl\n \nJ\n,","year":"2003"},{"key":"CIT0051","series-title":"Pharmacol Ther","first-page":"107618\u2013","article-title":"Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?","volume":"214:","author":"Bailly\n \nC\n,","year":"2020"},{"issue":"(3)","key":"CIT0052","series-title":"Agents and Actions","first-page":"298\u2013302","article-title":"The anti-inflammatory action of nepitrin, a flavonoid","volume":"12","author":"Agarwal\n \nOP","year":"1982"},{"key":"CIT0053","series-title":"Mol Cell Biochem","article-title":"Computational study of pomegranate peel extract polyphenols as potential inhibitors of SARS-CoV-2 virus internalization","author":"Suruc\u02c7ic\u2032\n \nR\n,","year":"2020"},{"issue":"(1)","key":"CIT0054","series-title":"BMC Complement Alternative Med","first-page":"47","article-title":"Anti-inflammatory potential of ellagic acid, gallic acid and punicalagin A&B isolated from Punica granatum","volume":"17","author":"BenSaad\n \nLA\n,","year":"2017"},{"key":"CIT0055","series-title":"Bioinform Biol Insights","first-page":"14:1177932220965505","article-title":"Targeting the GRP78-Dependant SARS-CoV-2 Cell Entry by Peptides and Small Molecules","author":"Allam\n \nL\n,","year":"2020"},{"key":"CIT0056","series-title":"Drug Dev Res","first-page":":10.1002\/ddr.21730","article-title":"Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study","author":"Maiti\n \nS\n,","year":"2020"},{"issue":"(1)","key":"CIT0057","series-title":"Scientific Reports","first-page":"13093","article-title":"In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication","volume":"10","author":"Touret\n \nF\n,","year":"2020"},{"issue":"(10)","key":"CIT0058","series-title":"NatRevi Microbiol","first-page":"593\u2013606","article-title":"Therapeutic strategies to target the Ebola virus life cycle","volume":"17","author":"Hoenen\n \nT\n,","year":"2019"},{"key":"CIT0059","series-title":"Antiviral Res","first-page":"165\u201372","article-title":"Synergistic drug combination effectively blocks Ebola virus infection","volume":"137:","author":"Sun\n \nW\n,","year":"2017"},{"issue":"(2)","key":"CIT0060","series-title":"Br J Pharmacol","first-page":"181\u201391","article-title":"Drug repurposing screens and synergistic drug-combinations for infectious diseases","volume":"175","author":"Zheng\n \nW\n,","year":"2018"}],"container-title":["Qatar Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2021\/1\/article-12.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2021\/1\/article-12.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2021\/1\/article-12.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:21:34Z","timestamp":1777310494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2021\/1\/article-12.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":120,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.5339\/qmj.2021.12","relation":{},"ISSN":["2227-0426"],"issn-type":[{"value":"2227-0426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}